Company Description
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance.
The company offers cerebrum, a small molecule platform for CNS small molecule therapies and solidus, an antisense oligonucleotide platform to discover and develop antisense oligonucleotide.
It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain to treat focal onset epilepsy; relutrigine for the treatment of developmental and epileptic encephalopathies; PRAX-020; and PRAX-050.
In addition, the company develops elsunersen, a clinical-stage ASO designed to regulate NaV1.2 expression for the treatment of SCN2A-DEE; PRAX-080; PRAX-090; and PRAX-100.
It has a license agreement with RogCon Inc.; and research collaboration and license agreement with Ionis Pharmaceuticals, Inc. The company was incorporated in 2015 and is based in Boston, Massachusetts.
Country | United States |
Founded | 2015 |
IPO Date | Oct 16, 2020 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 116 |
CEO | Marcio De'Souza |
Contact Details
Address: 99 High Street, 30th Floor Boston, Massachusetts 02110 United States | |
Phone | 617 300 8460 |
Website | praxismedicines.com |
Stock Details
Ticker Symbol | PRAX |
Exchange | NASDAQ |
Stock Type | Common Stock |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $19.00 |
CIK Code | 0001689548 |
CUSIP Number | 74006W108 |
ISIN Number | US74006W2070 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Marcio Silva De'Souza M.B.A. | President, Chief Executive Officer and Director |
Timothy Edwin Kelly | Chief Financial Officer and Treasurer |
Alex Nemiroff J.D. | General Counsel and Secretary |
Dr. Steven Petrou B.Sc. (Hons.), Ph.D. | Co-Founder and Chief Scientific Officer |
Lauren Mastrocola | Vice President of Finance and Principal Accounting Officer |
Dr. Karl Hansen Ph.D. | Chief Technical Operations Officer |
Alex Kane | Vice President of Investor Relations and Corporate Communications |
Kelly McCue | Chief People Officer |
Alyssa J. S. Wyant | Chief Regulatory and Quality Officer |
Megan T. Sniecinski | Chief Business Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 19, 2025 | SCHEDULE 13G | Filing |
Feb 28, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
Feb 28, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
Feb 28, 2025 | 10-K | Annual Report |
Feb 28, 2025 | 8-K | Current Report |
Feb 14, 2025 | SCHEDULE 13G/A | Filing |
Feb 14, 2025 | SCHEDULE 13G/A | Filing |
Feb 14, 2025 | SCHEDULE 13G/A | Filing |
Feb 14, 2025 | SCHEDULE 13G/A | Filing |
Feb 5, 2025 | SCHEDULE 13G | Filing |